News | April 08, 2022
Cadila Pharma launches world’s first three-dose rabies vaccine
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The new facility is scheduled to start operation in the first half of 2024
Supply increase to help meet growing global demand
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
The expansion makes Exothera one of the largest viral vector facilities in Europe
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Subscribe To Our Newsletter & Stay Updated
